Table 1

Baseline demographics, comorbidities and concomitant medications (main analysis set)

Cohort A (switched from VKA to dabigatran)Cohort B (newly initiated on dabigatran or a VKA)
Total (n=4100)Dabigatran (n=3179)VKA (n=2186)Total (n=5365)
Mean age, years (SD)70.5 (9.6)68.6 (10.1)68.5 (9.5)68.6 (9.9)
 Range, years  18–100  22–95  18–95  18–95
Age, n (%)
 <65 years1029 (25.1)1042 (32.8)723 (33.1)1765 (32.9)
 65 to <75 years1552 (37.9)1154 (36.3)803 (36.7)1957 (36.5)
 ≥75 years1519 (37.0)983 (30.9)660 (30.2)1643 (30.6)
Sex, n (%)
 Female1998 (48.7)1602 (50.4)1080 (49.4)2682 (50.0)
 Male2102 (51.3)1577 (49.6)1106 (50.6)2683 (50.0)
Mean (SD) weight, kg84.1 (16.2)82.8 (15.5)82.5 (15.0)82.6 (15.3)
Comorbidities, n (%)3541 (86.4)2651 (83.4)1986 (90.9)4637 (86.4)
 Blood and immune system62 (1.5)40 (1.3)29 (1.3)69 (1.3)
 GI/metabolic1618 (39.5)1044 (32.8)774 (35.4)1818 (33.9)
 Heart and blood vessels3390 (82.7)2548 (80.2)1904 (87.1)4452 (83.0)
 Previous MI95 (2.3)77 (2.4)78 (3.6)155 (2.9)
 CVA/previous TIA247 (6.0)168 (5.3)118 (5.4)286 (5.3)
 Previous CHD1048 (25.6)749 (23.6)625 (28.6)1374 (25.6)
 Hypertension (arterial)2921 (71.2)2228 (70.1)1689 (77.3)3917 (73.0)
 Lung285 (7.0)166 (5.2)131 (6.0)297 (5.5)
 Malignancy48 (1.2)28 (0.9)7 (0.3)35 (0.7)
 Urogenital system308 (7.5)217 (6.8)175 (8.0)392 (7.3)
 Other*632 (15.4)416 (13.1)270 (12.4)686 (12.8)
Concomitant medications, n (%)3542 (86.4)652 (83.4)1993 (91.2)4645 (86.6)
 Antacids393 (9.6)248 (7.8)167 (7.6)415 (7.7)
 Antidiabetes drugs687 (16.8)392 (12.3)344 (15.7)736 (13.7)
 Antihypertensive drugs3229 (78.8)2428 (76.4)1839 (84.1)4267 (79.5)
 Antiarrhythmic drugs1479 (36.1)1052 (33.1)805 (36.8)1857 (34.6)
 Antiplatelet drugs274 (6.7)307 (9.7)275 (12.6)582 (10.8)
 Lipid-lowering drugs1670 (40.7)1227 (38.6)920 (42.1)2147 (40.0)
 NSAIDs45 (1.1)34 (1.1)15 (0.7)49 (0.9)
 Other898 (21.9)487 (15.3)355 (16.2)842 (15.7)
  • *Includes depression, psoriasis, thyropathy, vertebral algic syndrome and osteoporosis.

  • CHD, coronary heart disease; CVA, cerebrovascular accident; GI, gastrointestinal; MI, myocardial infarction; NSAIDs, non-steroidal anti-inflammatory drugs; TIA, transient ischaemic attack; VKA, vitamin K antagonist.